Wnt7a Counteracts Cancer Cachexia

Area of Science:

• Muscle physiology
• Cancer biology
• Regenerative medicine

Background:

• Cancer cachexia is a debilitating metabolic condition with no effective treatments, causing significant mortality.
• Skeletal muscle wasting is a hallmark of cancer cachexia, impairing patient mobility and quality of life.

Purpose of the Study:

• To investigate the therapeutic potential of the extracellular ligand Wnt7a in treating cancer cachexia.
• To elucidate the mechanisms by which Wnt7a affects skeletal muscle anabolism and muscle stem cell function in the context of cancer cachexia.

Main Methods:

• In vitro studies using murine and human myotubes to assess Wnt7a's effect on the AKT/mammalian target of rapamycin (mTOR) pathway.
• Evaluation of Wnt7a's impact on muscle stem cell activation and differentiation in cancer cachexia models.
• In vivo experiments using a mouse model of cancer cachexia induced by C26 colon carcinoma cells.

Main Results:

• Wnt7a activates the anabolic AKT/mTOR pathway in myotubes, effectively preventing cachexia-induced muscle atrophy.
• A single Wnt7a application was sufficient to prevent atrophy, irrespective of the tumor type.
• Wnt7a improved muscle stem cell activation and differentiation, counteracting the impaired regeneration seen in cancer cachexia.
• Wnt7a demonstrated efficacy in preventing cancer cachexia in a preclinical mouse model.

Conclusions:

• Wnt7a exhibits a dual role in mitigating cancer cachexia by promoting muscle anabolism and restoring muscle stem cell function.
• Wnt7a represents a promising therapeutic candidate for ameliorating muscle wasting and improving outcomes in cancer cachexia patients.